tirzepatide and gastric sleeve vs Bariatric Surgery Tackling suboptimal clinical response after

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

Innovative pharmacological options are required to cope with the global diabesity pandemic

COVID-19 infection raises questions about continuing semaglutide therapy

Learn how Ozempic, Wegovy, and similar drugs may affect SIBO, IMO, IBS symptoms, and the gut microbiome.

On the other end of the OOP Rx spectrum, 1% of prescriptions in the U.A

Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response